TOP HEADLINES

Featured Story

Drug delivery: Fertile ground for pharma-device company partnerships?

BOSTON--Whether through collaboration with academia or buyouts of smaller players, panelists at the Partnership Opportunities in Drug Delivery conference concurred that Big Pharma is increasingly looking externally for innovation and using its size and financial to power candidates through clinicial and onto the market.

Stealthy, DNA-based 'nano-cocoons' deliver cancer-killing payloads

Researchers at NC State University and the University of North Carolina have developed a DNA-based delivery vehicle capable of acting as a Trojan horse in cancer cells. Using DNA as a cage instead of synthetic materials makes the vehicle less toxic to healthy cells and allows for the attachment of precise targeting mechanisms.

Intersect ENT says latest data on dissolving implants for chronic sinusitis are encouraging

Now-public Intersect ENT touted three studies in the International Forum of Allergy & Rhinology, saying the results of their clinical studies demonstrated the benefits of its Propel and investigational Resolve implants for use in patients following sinus surgery.

Alnylam releases data on its Phase II study of TTR-mediated amyloidosis patients

At the American Neurological Association's 2014 Annual Meeting in Baltimore, Alnylam released 6-month data on its Phase 2 open-label extension (OLE) study of patisiran (ALN-TTR02), a clinical-stage RNAi candidate for the treatment of TTR-mediated amyloidosis in patients with familial amyloidotic polyneuropathy.

Alnylam says it wants to enter larger disease areas using partnership-driven approach

RNAi specialist Alnylam is focusing on rare diseases at the moment (with the exception of hepatitis B), but Chief Business Officer Laurence Reid told investors at the Leerink Rare Disease Roundtable conference that the company is also looking to enter bigger markets via partnerships.

MORE NEWS

From Our Sister Sites

FierceMedicalDevices

St. Louis, MO-based Veran Medical closed a $12 million financing round. The company, specializing in thoracic navigation an biopsy for early detection of lung cancer, will use the funds toward continued commercial expansion in the U.S. and international launch of the Veran Thoracic Navigation System.

FierceMedicalDevices

Punctum plugs improve patient compliance and deliver drugs to the eye effectively, said the American Academy of Ophthalmology, citing the results of a Phase II study of Ocular Therapeutix's dexamethasone delivering plug, whose length is a fraction of the diameter of a dime.